What Happened to Neuralink Brain Implant (Telepathy & Blindsight)?
Neuralink, founded by Elon Musk in 2016, is developing implantable brain-computer interfaces (BCIs) to connect the human brain directly with computers. After years of animal testing and regulatory hurdles, the company received FDA approval for human trials in May 2023 and successfully implanted its first device, named Telepathy, into a human patient in January 2024. As of early 2026, Neuralink is scaling up its operations, aiming for high-volume production and automated surgical procedures, with 21 patients globally having received implants.
Quick Answer
Neuralink's brain implant, known as Telepathy, has progressed from initial human trials in January 2024 to being implanted in 21 patients worldwide by early 2026. The company is now focused on achieving high-volume production and fully automated surgical procedures in 2026, aiming to make the technology more widely available for individuals with severe neurological conditions. Additionally, Neuralink is developing 'Blindsight,' an implant designed to restore vision.
📊Key Facts
📅Complete Timeline14 events
Neuralink Founded
Elon Musk co-founds Neuralink with a team of scientists and engineers, aiming to develop ultra-high-bandwidth brain-machine interfaces.
Working Prototype Demonstrated
Neuralink showcases a working prototype of its implantable device and demonstrates its ability to record and stimulate brain activity in animals.
Pig Demonstration
Neuralink conducts a live demo, displaying the brain activity of a pig named Gertrude with a coin-sized implant, demonstrating the technology's ability to read and interpret brain signals.
FDA Approval for Human Trials
After an initial rejection in 2022, Neuralink receives U.S. FDA approval for its first-in-human clinical trial, the PRIME Study, to evaluate the safety and functionality of its N1 implant and R1 surgical robot.
Human Trial Recruitment Begins
Neuralink begins recruiting participants for its PRIME Study, focusing on individuals with quadriplegia due to cervical spinal cord injury or amyotrophic lateral sclerosis (ALS).
First Human Implanted
Neuralink successfully implants its brain-computer interface, named 'Telepathy,' into its first human patient, Noland Arbaugh, a quadriplegic. Elon Musk announces the patient is recovering well.
First Patient Demonstrates Thought Control
Noland Arbaugh publicly demonstrates his ability to control a computer cursor and play chess using only his thoughts via the Neuralink implant, showcasing the device's functionality.
Blindsight Receives FDA Breakthrough Designation
Neuralink receives FDA Breakthrough Device Designation for 'Blindsight,' an implant aimed at restoring vision, indicating an acceleration of its development and regulatory review.
International & Robotic Arm Trials Launched
Neuralink launches the CAN-PRIME Study in Canada, its first international trial, and the CONVOY Study to evaluate BCI control of an assistive robotic arm.
Speech Restoration Breakthrough Designation
Neuralink receives FDA Breakthrough Device Designation for its technology aimed at restoring communication for individuals with severe speech impairment.
$650M Series E Funding Round
Neuralink closes a $650 million Series E funding round, valuing the company at approximately $9 billion to $9.65 billion, providing significant capital for expansion.
12 Patients Implanted Globally
Neuralink announces that 12 people worldwide with severe paralysis have received its N1 implants and are actively using them to control digital devices.
First Patient Teases 'Big News'
Noland Arbaugh, the first human recipient, provides a 21-month update, expressing optimism and teasing 'big news' for his two-year update in early 2026.
High-Volume Production & Automated Surgery Announced
Elon Musk announces Neuralink's plans to begin 'high-volume production' of its brain chips and transition to 'almost entirely automated surgical procedures' in 2026. The company also reports 21 global trial participants.
🔍Deep Dive Analysis
Neuralink, established by Elon Musk in 2016, embarked on an ambitious mission to create ultra-high-bandwidth brain-machine interfaces, driven by Musk's vision of human-AI symbiosis and a desire to assist individuals with neurological disorders. The company spent its initial years in research and development, including extensive animal testing, which drew both scientific interest and significant ethical scrutiny regarding animal welfare.
A pivotal turning point arrived in May 2023 when Neuralink received approval from the U.S. Food and Drug Administration (FDA) to commence its first human clinical trial, the PRIME study, after an initial rejection in 2022 due to safety concerns. This approval paved the way for the first human implantation of Neuralink's 'Telepathy' device in January 2024, into Noland Arbaugh, a 29-year-old quadriplegic. Arbaugh's subsequent public demonstrations, where he controlled a computer cursor and played games like chess using only his thoughts, garnered widespread attention and showcased the implant's potential to restore independence.
Throughout 2024 and 2025, Neuralink continued to expand its clinical trials. By September 2025, 12 patients globally had received implants and were actively using them to control digital devices. The company also secured substantial funding, including a $650 million Series E round in June 2025, which valued Neuralink at approximately $9 billion to $9.65 billion. In addition to 'Telepathy' for motor control and communication, Neuralink received FDA Breakthrough Device Designations for 'Blindsight' (vision restoration) in September 2024 and for speech restoration in May 2025, indicating a broader therapeutic scope.
As of March 2026, Neuralink is poised for a significant expansion. Elon Musk announced in January 2026 that the company plans to initiate 'high-volume production' of its brain-computer interface devices and transition to 'almost entirely automated surgical procedures' this year. This move aims to streamline the implantation process, potentially reducing surgical risks and recovery times by allowing device threads to pass through the dura without its removal. The number of implanted patients had grown to 21 globally by January 2026, with the first UK patient also reported. While the company's rapid progress is celebrated for its potential to transform lives, it continues to face criticism regarding transparency, ethical considerations, and the balance between medical device development and its long-term transhumanist goals.